Heart Failure
Dapagliflozin reduces risks of kidney failure, cardiovascular or renal death
Dapagliflozin reduced the worsening of kidney function and the risk of cardiovascular or renal death in patients with chronic kidney disease irrespective of the underlying cause of kidney disease, according to recently presented data.
BAMI
Effect of autologous cell-based therapy on HF hospitalization in patients with acute MI.
Female authors underrepresented in HF randomized controlled trials
Women have remained underrepresented as authors of HF randomized controlled trials from 2000 to 2019, researchers found in a systematic review.
1 in 5 high CV-risk patients may experience an event after noncardiac surgery
Among high-CV risk patients who underwent noncardiac surgery, up to one-fifth could experience a major adverse CV event within 1 year of their procedure, according to research published in European Heart Journal: Acute Cardiovascular Care.
Transcatheter device may benefit patients with HF waiting for transplantation
A transcatheter device was a safe and effective bridge strategy to heart transplantation in patients with end-stage HF, with 23.5% removed from the list due to clinical improvement, researchers found in the MitraBridge registry.
Blood volume analysis may help guide treatment in HF hospitalization at low cost
Evaluation of blood volume phenotypes may not only guide treatment in HF hospitalization, but may also be cost-effective for patients, according to two posters presented at the virtual Heart Failure Society of America Scientific Meeting.
Polypharmacy significantly increased in HF hospitalizations from 2003 to 2014
Polypharmacy, or the condition of taking a high burden of medications, is common in hospitalized patients with HF at admission and discharge, and has increased from 2003 to 2014, researchers found.
Ultrafiltration could reduce 1-year rehospitalization in acute decompensated HF
Ultrafiltration for acute decompensated HF reduced hospital readmission by 1.74 visits in the following 12 months compared with the prior year, according to data presented at the virtual Heart Failure Society of America Scientific Meeting.
Ablation of right greater splanchnic nerve may benefit in HFpEF
Endovascular ablation of the right greater splanchnic nerve improved quality of life and exercise capacity in patients with HF with preserved ejection fraction, according to findings from a first-in-human study.
GALACTIC-HF, STRENGTH among late-breaking trials to be presented at virtual AHA meeting
Research in HF, omega-3 fatty acids, cardiac imaging among women and drug-eluting stents are among the topics of late-breaking clinical trials being presented at the virtual American Heart Association Scientific Sessions.